The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Related party transaction with affiliated company

12 Sep 2016 10:01

RNS Number : 5542J
Samsung Electronics Co. Ld
12 September 2016
 

Related party transaction with affiliated company

 

Samsung Electronics Co., Ltd. (KS005930, KS005935, SMSN, SMSD) ("SEC") announced today that its Board of Directors have authorized a transaction with Samsung Securities Co., Ltd., an affiliated company of SEC.

 

 

Details

 

1. Date of Transaction: October 24, 2016

 

2. Terms of Transaction:

 

Start Date

October 24, 2016

End Date

November 30, 2016

Object of Transaction

Securities

Transaction Value

KRW 82,375 million

Type of Agreement

Firm commitment underwriting

 

3. Total Value of Transaction: KRW 82,375 million

 

4. Number of Independent Directors Present at the BOD Meeting: 5 (100%)

 

5. Attendance of Audit Committee: Yes

 

6. Others

  - The purpose of the contract is to sell the shares of Samsung Biologics owned by SEC through an initial public offering of Samsung Biologics. The transaction will be conducted through a firm commitment underwriting. Samsung Securities, the underwriter, will purchase the shares for approximately KRW 82,375 million (661,000 shares with face value of KRW 2,500).

 

 - The registered and start date of the above transaction is the date the firm commitment underwriting agreement is executed, and the end date will be the due date of fee payment, which will be finalized in the agreement. Samsung Biologics applied for preliminary approval from KRX on August 12 but this approval is still pending at this time. After completion of the review, the firm commitment underwriting agreement will be finalized and executed shortly before the submission of securities registration statement.

 

 - The transaction value and the number of shares may change during the process of finalizing the firm commitment underwriting agreement and the offering price may change according to the demand forecast.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUQABUPQURP

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.